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Introduction
Dilated cardiomyopathy (DCM) is a primary myocardial 
disorder characterized by cardiac enlargement and im-
paired systolic function of one or both ventricles. Despite 
conventional therapies the prognosis remains poor, with 
a mortality rate of 10% [1-3]. Even if the assessment of 
Quality of Life (QoL) has become a challenging issue in 
the scientific debate [4], only few studies have evaluated 
the burden of illness and the impact of the disease natu-
ral history on QoL for the individual with DCM. 
After the systematization given to the subject of QoL 
evaluation by Schumacher and Olschewski [5, 6] differ-
ent modes of assessing the quality of life have been de-
scribed, distinguishing among: (i) First Order, or ascer-
tainment using validated measuring questionnaires; (ii) 
Second Order, or objective measurements (for example 
sleep dysfunction, general well being, motor function-
ing); (iii) Third Order, where only proxies for the qual-
ity of life are known, as for example the hospitalization 
history of the patient. 
The analysis of non-fatal recurring events, for exam-
ple repeated admissions, is appropriate in studies on 
chronic-degenerative diseases implying that the patient 
passes from an acute phase to another acute phase or 
worse. In this case, the patient’s hospitalization rate, 
being associated with a high familiar, social and eco-
nomic burden, is considered as evidence of the severity 
of the disease [7, 8]. Thus, the underlying hypothesis 
is that QoL decreases when the hospitalization rate 
increases, as typically happens for DCM patients in 
which clinical picture progresses from asymptomatic 
left ventricular dysfunction to overt symptomatic heart 
failure [9, 10]. Studies performed in other clinical set-
ting [11, 12] validated measuring questionnaires in or-
der to evaluate the impact of exacerbation on health 
status and admission to hospital testify the negative ef-
fect of hospitalization on QoL confirming the correct-
ness of assumption on which a third order evaluation 
is based on.
However, very few models have been proposed in order 
to assess QoL starting from proxy such as hospitaliza-
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Summary
Rationale, aims and objectives. Some objective indicators like 
symptoms, toxicity, performance status, rate of hospitalization or 
re-employment have been already employed in scientific litera-
ture as proxies of Quality of Life assessment, and, in spite of the 
intrinsic limitations of such a measurement, they represent a valu-
able source of information in all the situations where a formal 
assessment is impossible, due to budget, time or human resources 
constrains. We concentrate here on some models for the analysis 
of frequency of hospitalization data and we discuss an application 
to the Hearth Muscle Disease Study Group data.
Methods. A sample of 235 patients with dilated cardiomyopathy 
(DCM) prospectively treated at the Department of Cardiology 
(Trieste, Italy) have been observed during a period of 18 years, 
from 1978 to 1992 and data regarding hospitalization history 
were collected. The hospitalization process depends on the time 
since the last event, and usually is a function of a set of explana-
tory variables, such as the current state of the patient, treatments 
he has been receiving and the severity of disease.
We propose here a semi-Markov representation of the hospitali-
zation process, and we analyze data regarding DCM, implement-
ing Exponential, Weibull, and Cox models; in Cox models we take 
care also of the stratification according to the duration or to the 
levels of the state factor.
Results. The probability of experiencing a second hospitaliza-
tion within one year after the first one is estimated about 0.50, 
and within two years about 0.30. After this point the probability 
remains constant at a 0.10 level. The same pattern is observed for 
the second hospitalization, while things are getting worse after 
the third hospitalization, when the probability of not having a sub-
sequent hospitalization is about 0.10 within one year. Betablock-
ers have a strong influence in enlarging the time interval spent 
between an hospitalization and the other. 
Conclusions. The hospitalization process can be viewed only 
as a rough approximation of the good standing of the patient. 
However, for diseases like DCM can be reasonable, because of 
the relatively fast increment in the worsening conditions of the 
patients and the consequently high chances of observing new hos-
pitalizations up to the absorbing state (the death). Moreover a 
very detailed modeling of the process leads to extract as much 
information as possible from the data. 
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tion rate. Generally, the hospital history of the patient is 
considered as a “follow-up” and the subject becomes the 
protagonist of a Markov process at the finished states, 
whose transitions between states correspond to the oc-
currence of one or more events of interest [13]. Multi-
state models that exploit the properties of Markov chains 
are widely used in medical research because they have 
a methodological framework useful to describe complex 
outcomes which are dependent on time [14]. The ear-
lier applications of multi-state model have been done 
with homogeneous Markov models, which assume that 
the transition intensities do not depend on time [15]. A 
slightly more general model is to consider that the tran-
sitions depend, in addition to time, on the time spent in 
the present state, which makes sense in QoL since the 
length of hospitalization is an evidence of the inability to 
conduct a satisfactory life, which defines a Semi-Mark-
ov model.
A first discussion has been given by Andersen [16] who 
proposed a class of Semi-Markov models to analyze 
the hospitalization rate. The advantage of using Semi-
Markov models relies on the fact they allow for a hos-
pitalization rate, which varies depending on the time (a 
non constant intensity of the process moving from one 
state to another). Nevertheless they can be reduced to 
constant intensity Markov model when the rate does not 
vary within transitions.
In the present paper the application of Semi-Markov 
models to describe the hospitalization process, as proxy 
of the QoL, in individuals affected by DCM, is proposed. 
Hospitalization rates are estimated considering treat-
ments patients have been receiving, giving thus some 
insight to investigate their influence on the intensity 
(duration) of the process. A short introduction to Semi-
Markov models, both in parametric and semi-parametric 
form, is given and their application to the DCM patients 
is discussed. 
Methods
Data collection
The HMSDG (Hearth Muscle Disease Study Group) da-
taset is a Hospital Registry, which enrolled 235 patients 
affected by the dilated cardiomiopathy. The patients 
have been observed during a period of 15 years, from 
1 Janauary 1978 to 31 December 1992, at Maggiore 
Hospital, Department of Cardiology, in Trieste (Italy). 
The end points of follow up were heart transplantation 
or death. The follow up data were obtained by regular 
hospital visits [17].
Only in the very last years a systematic collection of 
data about QoL has been undertaken using mainly 
the Minnesota Living with Heart Failure Question-
naire [18], whereas for earlier years the only data 
available on QoL are based on the patients’ history of 
hospitalization. Data regarding pharmacological treat-
ment were also collected, including pharmacotherapic 
choice (Betablockers, ACE-inhibitors) and time at first 
assumption. 
Duration models
In analogy to irreversible illness-death models, a Markov 
model can be assumed for modeling multistate phenom-
enon such as hospitalization histories. Given the maxi-
mum number of observed hospitalizations in a cohort of 
patients, the process of hospital admission can be viewed 
as a forward-moving Markov Chain, in which the only 
possible transitions from the actual state (the progressive 
number of hospitalization) are to a new hospitalization 
or to the absorbing state (the death). However, modeling 
hospitalization histories is more complex than modeling 
a simple point-process as that described above, since the 
risk of being hospitalized is not only dependent on the 
time (duration) but also on other factors, such as the cur-
rent state of the patient, treatments he has been receiving 
and the severity of disease. Furthermore, in some cases 
also the risk may depend on the time. 
In this setting, patient’s hospitalization history can be 
assumed to result from Semi-Markov process, i.e. the 
time-dependent state transition probability from one 
state (one hospitalization) to another depends only on 
its previous state. Based on this assumption, the Cox’s 
proportional hazard-model [19, 20] can be applied to es-
timate the time dependent state transition probability. 
In the Cox’s proportional hazard-model is usally written 
in term of the hazard, or intensity, function h(t), which 
represents the instantaneous changing rate of state at 
time t, i.e the risk to experience a hospitalization given 
survival up to time t. Following McCullagh [19], h(t) 
can be modeled as functions of a set of predictor vari-
ables x and the time t and can be specified as: 
  (1)
The model (1) belongs to the class of the intensity-based 
models, with an intensity function not constant over the 
time. Given the nature of h(t), the model could be para-
metric or semi-parametric. In the parametric setting, the 
Weibull and the Exponential distribution can be used to 
define the form of the hazard function h(t). The main 
difference between these models relies on the definition 
of h(t). In the Exponential model the intensity is constant 
over time, while it is assumed as a power function of the 
time in the Weibull model. 
On the contrary, the Cox Proportional Hazard Model 
does not specify any form of the hazard function h(t) 
and this property makes Cox models semi-parametric 
models.
In our setting, the intensity function can be supposed 
joined with a treatment factor for a global effect within 
each state. Thus the hazard function can be stratified ac-
cording to the patient’s state. This assumption is equal to 
assume, that the time dependent term λ(t), and thus the 
hazard function, is different in each stratum [20].
In the following analysis, we considered Exponential, 
Weibull, Cox models and stratified Cox Model to assess 
the hospitalization rate of patients affected by the dilated 
cardiomiopathy. The transition hazard rates between dif-
ferent states were estimated with respect to treatments. 
The estimated coefficients of treatments provided useful 
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insight to investigate their influence on state and dura-
tion on the state. 
In all these models we did not consider the potential cor-
relation among observations given by the subject effect 
i.e.: the fact that we have more than one transition (at 
least potentially) for each subject due to repeated ad-
missions. Several methods have been proposed to take 
into account the dependencies in the data such as frailty 
models [21] or marginal hazard methods [22, 23]. In this 
study we considered a marginal hazard approch in or-
der to adjust the standard errors of the estimates for the 
dependency in the data applying the Wei-Lin-Weissfeld 
method [23].
Results
Out of the total of the patients, 48 experienced only one 
hospitalization, 66, 43 and 22 patients had respectively 
2, 3 and 4 hospitalizations. Finally 56 patients had more 
than or exactly 5 hospitalizations (the actual maximum 
number of hospitalizations is 13 which was observed in 
one patient). 
In Figure 1, Kaplan-Meier curves of new hospitalization 
were obtained separately for each state. The estimates of 
the transition probabilities give some indications on the 
frequency and rate at which one hospitalization follows 
the previous one. The probability of experiencing a sec-
ond hospitalization within one year after the first one is 
estimated about 0.50, and within two years about 0.30. 
After this point the probability remains constant at a 0.10 
level (State 2 curve). The same pattern is observed after 
the second hospitalization (State 3 curve), where the 
probability of not having another hospitalization within 
one year is about 0.50, remaining constant for the subse-
quent years. Things are getting worse only after the third 
hospitalization (State 4 and State 5 curves), where the 
probability of not having a subsequent hospitalization is 
about 0.10 within one year. 
The results are presented as follow: (i) a measure to 
compare the goodness of fit for the different models is 
reported in Table I; (ii) coefficients of explanatory varia-
bles estimated by models are given in Table II and Table 
III; (iii) standard error to assess statistical significance of 
coefficients are also reported; for Cox models stratified 
robust standard error have been computed too.
In Table I, the log-likelihood for the different models is 
shown. Log-likelihood is a pragmatic measure to com-
pare models (the larger the value is, the better the model 
is). Exponential and Weibull have almost the same log-
likelihood, giving the suggestion that the exponential 
or the Weibull models, which have a constant intensity 
function, could be adequate to represent the process. 
Explanatory variables coefficients for these parametric 
models are shown in (Tab. II). The Cox model stratified 
by states performs better than the analogous stratified by 
duration, which correspond to a non-constant intensity 
Markov process (Tab. I). 
Treatment effect for Cox model stratified by state is al-
ways significant (Tab. III), meaning they influence the 
duration in a state. Betablockers in particular have a 
stronger influence in enlarging the time interval spent 
between a hospitalization and the other. Their positive 
effect is twice as bigger in the most critical regions in the 
state-space: the third and fourth hospitalization, where 
the patient overcomes a threshold, which usually drives 
him into a worsening condition (Fig. 1). Standard errors 
obtained for the proportional hazard model stratified by 
state using normal approximation and robust estimation 
are given in Table III. The robustified standard errors are 
about 20% more conservative than those based on inde-
pendence assumptions. However, this does not change 
our conclusions about treatment effect. 
Discussion
Studies that illuminate the complex relationships among 
disease status and global quality of life can inform a 
broad range of topic, including those involving the scope 
and focus of clinical care, the access to care, and health 
care policies [24]. However, the possibility to imple-
ment this kind of studies is limited in all the situations 
where a formal assessment is impossible, due to budget, 
time or human resources constrains. On the other hand, 
Fig. 1. time in a State before a new hospitalization (in days). the 
State 1 curve depicts the probability of the first admission to the 
hospital in patients with dcm. the State 2, the State 3, the State 
4 and the State 5 curves depict the probability of experiencing 
a hospitalization after the first, the second, the third and the 
fourth one, respectively.
Tab. I. log-likelihoods for exponential, Weibull, cox models and cox stratified (by state and by duration) models. the larger the value of the 
log-likelihood is, the better the model is.
Model Exp. Weibull Cox Cox (State) Cox (Duration) 
null -754.24 -739.46 -998.82 -763.03 -837.5 
(Beta+ace) -739.21 -729.07 -959.70 -748.19 -826.37 
(Beta+ace)*State -659.38 -659.38 -949.97 - -796.52 
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even when only proxies for the quality of life are known, 
an adequate modeling choice could be able to give an 
estimate of diseases burden and point out major issues 
in clinical management.
The application of Semi-Markov models to describe the 
dynamic of quality of life in DCM patients in long-term 
follow-up has been shown to be a flexible and a real-
istic choice. In particular, the detailed modeling of the 
hospitalization process, whether considered a proxy of 
the quality of life, could be useful to detect impact of 
therapy in reducing hospitalizations, or in describing the 
natural history of the disease form a broader perspective. 
In our setting, according to the log-likelihood, semi-par-
ametric Cox model stratified by states and the paramet-
ric Exponential and Weibull models seems to be simi-
larly adequate to modeling the process. On the contrary, 
Cox model stratified by duration appears to be a poorer 
model, suggesting that constant intensity transitions are 
adequate in modeling the process and that they do not 
depend on events of the history of the process. 
The natural history of DCM, as depicted by the hospi-
talization rate, seems to consist in a highly progressive 
worsening scenario. The probability of being re-hos-
pitalized within one-year is about 90% after the third 
hospitalization, indicating a highly severe prognosis in 
this class of patients. Moreover, such a high re-hospi-
talization probability is most likely indicating a poor 
chance of having an independent life and a normal pro-
fessional activity for these patients. High hospitaliza-
tion episodes could also leads to have or exacerbates 
psychological symptoms such as depression and anxi-
ety. These psychological symptoms and the stressful 
experience of frequent re-hospitalizations, in turn, can 
initiate a spiraling decline in physical and psychological 
well-being and can affect also the course of the cardiac 
disease [25, 26].
Our results stress the key role of a timely diagnosis and 
of a well-planned, pharmacotherapic management pro-
gram: treatment seems in fact to be fundamental to re-
duce the burden of illness. Neurohormonal antagonists 
like Aceinihibitors and Betablockers were showed to 
improve prognosis in heart failure [27] and, as expected, 
were always significant in present analysis. Betablock-
ers in particular, cause a dramatical improvement of the 
left ventricular function [28]. The strong influence of 
metoprolol in enlarging the effects of sympathetic ac-
tivation in patients with more severe heart failure [29] 
may explain the fact that treatment effect is twice as 
bigger in the third and fourth hospitalization, and may 
suggest a greater effect of Betablockers in more severe 
patients; even if a possible confounding due to the fact 
that the drug could be evolved during the long time of 
observation of the study could be considered. 
Indeed, the limitation of the data does not allow getting 
more insight into this process. The hospitalization his-
tory can be, in fact, viewed only as a rough approxima-
tion of the good standing of the patient. For diseases like 
DCM can be reasonable, because of the relatively fast 
increment in the worsening conditions of the patients and 
the consequently high chances of observing new hospi-
talizations up to the absorbing state (the death). More 
generally, this kind of approach is the only one feasible 
in the analysis of long term open trials, hospital registry 
data, where usually ad hoc QoL assessment covers only 
a small portion of the total registry population. Moreo-
ver even if, deeper observation using questionnaires or 
ad hoc subjective and objective measurements should 
be used whenever possible, when such information is 
not available, a very detailed modeling of the process 
leads to extract as much information as possible from 
the data. 
Tab. II. coefficients and Standard errors (Se) for the parametric models.
Weibull Exponential
Term Coeff. SE Coeff. SE 
int. 7.94 0.11 7.95 0.11 
Beta -0.23 0.15 -0.24 0.15 
ace -0.42 0.16 -0.41 0.15 
State 2 -0.92 0.22 -0.91 0.21 
State 3 -2.07 0.32 -2.04 0.30 
State 4 -1.24 0.41 -1.21 0.39 
State 5 -1.80 0.33 -1.75 0.32 
Beta.State 2 -0.29 0.36 -0.28 0.35 
Beta.State 3 1.21 0.45 1.22 0.44 
Beta.State 4 1.35 0.60 1.37 0.57 
Beta.State 5 0.38 0.43 0.39 0.41 
ace.State 2 -0.10 0.32 -0.10 0.31 
ace.State 3 -0.12 0.44 -0.14 0.42 
ace.State 4 -0.96 0.60 -0.99 0.57 
ace.State 5 0.27 0.40 0.237 0.39 
log(scale) 0.03 0.03 
Tab. III. coefficients, odds ratio (Or), native and robust Standard errors 
(Se) for the cox model stratified by State. robust Se have been esti-
mated adjusting for repeated observation on the same subject. 95% 
confidence interval (ci) for Or were calculated base on robust Se.
Treatment coef OR (95% CI) Native 
SE 
robust 
SE 
Beta 0.409 1.51 (1.17; 1.94) 0.126 0.131 
ace 0.596 1.81 (1.28; 2.57) 0.132 0.178 
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